Experience of Fibrosing Cholestatic Hepatitis With Hepatitis C Virus in Kidney Transplant Recipients

Siddiqui, A.R.; Abbas, Zaigham; Luck, Nasir Hassan; Hassan, Syed Mujahid; Aziz, Tahir; Mubarak, Muhammed; Naqvi, Syed Arsalan Ahmed; Rizvi, Syed Adib-ul-Hasan

doi:10.1016/j.transproceed.2011.12.019

Cited by 18 publications

(15 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This entity is difficult to treat and is associated with high morbidity and mortality rates, and its treatment is associated with risk of graft rejection 42,43. Survival of patients with fibrosing cholestatic hepatitis improves with early initiation of PEGylated interferon (IFN)-α2a and ribavirin therapy, strict monitoring by biopsy and HCV load determinations, and replacement of tacrolimus with cyclosporine 44.…”

Section: Hcv Infection In Kidney Transplant Recipientsmentioning

confidence: 99%

Management of chronic hepatitis C virus infection in patients with end-stage renal disease: a review

Valadez

Juárez

Pedrero

et al. 2015

TCRM

View full text Add to dashboard Cite

Infection with hepatitis C virus (HCV) is highly prevalent in chronic kidney disease (CKD) patients, mainly in those on hemodialysis (HD). The seroprevalence of HCV in developing countries ranges between 7% and 40%. Risk factors for this infection in the CKD population include the number of blood transfusions, duration of end-stage renal disease (ESRD), and prevalence of HCV in HD. Chronic HCV infection in patients with ESRD is associated with an increase in morbidity and mortality in the pre and post kidney transplant periods. The increase in mortality is directly associated with liver complications and an elevated cardiovascular risk in HCV-infected patients on hemodialysis. Antiviral treatment may improve the prognosis of patients with HCV, and standard interferon remains the cornerstone of treatment. Treatment of HCV in patients with CKD is complex, but achieving a sustained viral response may decrease the frequency of complications after transplantation. It appears that HCV-infected patients who remain on maintenance dialysis are at increased risk of death compared with HCV patients undergoing renal transplantation.

show abstract

Section: Hcv Infection In Kidney Transplant Recipientsmentioning

confidence: 99%

Management of chronic hepatitis C virus infection in patients with end-stage renal disease: a review

Valadez

Juárez

Pedrero

et al. 2015

TCRM

View full text Add to dashboard Cite

show abstract

“…5 Owing to the increased risk of acute allograft rejection, adverse events, and decreased efficacy, interferon is contraindicated in RTRs except in cases of life-threatening vasculitis or fibrosing cholestatic hepatitis. 4,5,16 Because there is no recommended treatment regimen for HCV in RTR, avoiding antilymphocyte antibodies, decreasing corticosteroid dose, and switching from tacrolimus to cyclosporine are among case management strategies. 5 However, recently approved DAAs have revolutionized the treatment of HCV owing to their shorter treatment duration, little to no drug resistance, and interferonfree regimen.…”

Section: Discussionmentioning

confidence: 99%

Untitled

Hanif

Laeeq²,

Mandhwani³

et al. 2017

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: Although direct-acting antiviral agents have revolutionized hepatitis C virus treatment, these novel agents are not widely available in the developing world. Further, no treatment recom mendation for renal transplant recipients includes these agents. We aimed to evaluate the effectiveness of sofosbuvir and ribavirin, the only direct-acting antiviral agents available in Pakistan, in renal transplant recipients.

show abstract

“…In addition, fibrosing cholestatic hepatitis (FCH) can occur in HCV-infected patients following KT [20] . It typically develops during the period of maximal immunosuppression (1-4 mo after KT) and is associated with progressive cholestatic, mild elevation of serum alanine aminotransferase (ALT), and high HCV viremia level [20][21][22] . FCH is associated with very high morbidity and mortality rates.…”

Section: Ktmentioning

confidence: 99%

“…FCH is associated with very high morbidity and mortality rates. IFN-based treatment is often ineffective and is associated with a risk of graft rejection [20][21][22] .…”

Section: Ktmentioning

confidence: 99%

Management of patients with hepatitis C infection and renal disease

Bunchorntavakul

Maneerattanaporn

Chavalitdhamrong

2014

WJH

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection in patients with end-stage renal disease (ESRD) is associated with more rapid liver disease progression and reduced renal graft and patients' survival following kidney transplantation. Evaluations and management of HCV in patients with renal disease are challenging. The pharmacokinetics of interferons (IFN), ribavirin (RBV) and some direct acting antiviral (DAA), such as sofosbuvir, are altered in patients with ESRD. With dose adjustment and careful monitoring, treatment of HCV in patients with ESRD can be associated with sustained virological response (SVR) rates nearly comparable to that of patients with normal renal function. DAA-based regimens, especially the IFN-free and RBV-free regimens, are theoretically preferred for patients with ESRD and KT in order to increase SVR rates and to reduce treatment side effects. However, based on the data for pharmacokinetics, dosing safety and efficacy of DAA for patients with severe renal impairment are lacking. This review will be focused on the evaluations, available pharmacologic data, and management of HCV in patients with severe renal impairment, patients who underwent KT, and those who suffered from HCV-related renal disease, according to the available treatment options, including DAA.

show abstract

Experience of Fibrosing Cholestatic Hepatitis With Hepatitis C Virus in Kidney Transplant Recipients

Cited by 18 publications

References 19 publications

Management of chronic hepatitis C virus infection in patients with end-stage renal disease: a review

Management of chronic hepatitis C virus infection in patients with end-stage renal disease: a review

Untitled

Management of patients with hepatitis C infection and renal disease

Contact Info

Product

Resources

About